arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Invivyd, Inc.

IVVD
$0.74 ▲ +0.09 (+13.55%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
6 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Invivyd, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $127.4M
Dividend Yield
Revenue Growth 110.5%
Op. Margin -104.0%
ROIC -18.2%
FCF / Share $-0.34
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

6-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$53.43M
↑ +110.5%
Net Income Profit after all expenses
$-52.49M
↑ +69.1%
FCF / Share Free cash flow per share
$-0.34
↑ +76.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
27
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters